Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 11/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15887337 | 0.88 | ALDH1A1 (0.42) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL28135188 | 0.86 | GAA (0.44) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL4129677 | 0.85 | AKR1C3 (0.47) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL287468 | 0.85 | ALDH1A1 (0.63) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL15451317 | 0.84 | EPHX1 (0.50) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL732665 | 0.83 | AKR1C3 (0.55) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL112764 | 0.83 | AKR1C3 (0.59) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL11090811 | 0.83 | KMT2A (0.53) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL10922696 | 0.83 | PTGS1 (0.55) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 | |
| SCHEMBL2367665 | 0.80 | ALDH1A1 (0.57) | AKR1C3AKR1C2PTGS2PTGS1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453724-A | Sulfonylmaleimide-based linkers and corresponding conjugates | 皮埃尔法布雷医药公司 | 2021-09-28 | — | — | CN | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | AKR1C3 2280/4885AKR1C2 2020/4885PTGS2 4421/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | AKR1C3 4524/4885AKR1C2 4616/4885PTGS2 3443/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | AKR1C3 2536/4885AKR1C2 2212/4885PTGS2 2742/4885 |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | AKR1C3 1393/4885AKR1C2 1513/4885PTGS2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.